![]() |
Who Owns Science? Promises and Pitfalls of the Public-Private Partnerships
Event Summary
Who Owns Science? Promises and Pitfalls of the Public-Private Partnerships
Scope:
Speakers:
Registration:
If you require shuttle bus transport from the Genome Campus, please indicate your requirements here Live Stream:
Genome Campus Shuttle Bus:
Chair and OrganisersThis conference is hosted by the EBI as a part of the EMBL-EBI Science and Society programme . Symposium chair
Organising Committee
ContactProgrammeThe programme will include 4 individual talks by invited speakers and a 1 hour open discussion period with all speakers.
Live StreamThe talks as well as the panel discussion will be broadcast here live from the event. John SulstonBorn in Buckinghamshire in 1942, Sir John Sulston obtained his first degree from Cambridge University in 1963. He stayed in Cambridge to pursue a Ph.D., working on nucleotide chemistry which he completed in 1966. After embarking to the Salk Institute in the USA to do post-doctoral work, he eventually returned to Cambridge in 1969 to join Sydney Brenner's lab at the MRC Laboratory of Molecular Biology. It was here where he started working on the nematode worm John also played a central role in both the Since retiring from his position as a director in 2000, John has been an outspoken and active voice in the discussion of the ethics and politics of science with a focus on free release, intellectual property and global inequality. In 2007, he was appointed chair of the newly founded Institute of Science, Ethics and Innovation at the University of Manchester. Amongst numerous other awards, John is a Fellow of the Royal Society and an honorary fellow of Pembroke College, Cambridge. Prof. Sir John Sulston, Institute for Science, Ethics and Innovation, University of Manchester Tim HubbardTim graduated with a BA in Biochemistry from University of Cambridge in 1985 and a PhD in Protein Design from the Department of Crystallography, Birkbeck College, London in 1988. Following a postdoctoral fellowship at the Protein Engineering Research Institute in Osaka under the EU scientific training program in Japan (1989-90) he returned to Cambridge becoming a Zeneca Fellow at the Medical Research Council (MRC), Centre for Protein Engineering. In 1997 he joined the Wellcome Trust Sanger Institute to become Head of Human Genome Analysis. He has been Head of Informatics and a Board of Management member since 2007. Tim has served on many national and international advisory boards including the advisory council of the RIKEN Genome Science Centre, Japan as chairman (2005-2007), the Expert Group on European research infrastructure for genomics, bioinformatics, animal resources, proteomics, and structural biology of the European Strategy Forum for Research Infrastructures (ESFRI) (2005-2006), the advisory board of ukPMC (UK PubMedCentral) as deputy chair (2007-), the steering group of the National Genetics Reference Laboratories (NGRL) (2007-) and the E-Health Records Research Board of the UK Government Office for Strategic Coordination of Health Research (OSCHR) (2007-). In his private capacity he is also significantly involved in international policy discussions around innovation, intellectual property and public health. Dr. Tim Hubbard, Wellcome Trust Sanger Institute, Hinxton David Searls In 1991 he returned to Penn as Research Associate Professor of Genetics, with a secondary appointment in Computer and Information Science. During this time he co-founded the meeting series Intelligent Systems for Molecular Biology (ISMB) and was a founding board member of the International Society for Computational Biology (ISCB). In 1995 he moved to SmithKline Beecham Pharmaceuticals, where he became VP of Bioinformatics. At the time of the GlaxoSmithKline merger in 2001, he was appointed Senior VP, responsible for informatics support at five sites in the US and Europe. He left GSK in late 2008, and is now an independent consultant. He currently serves on the Informatics Advisory Committee of the Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation, the Protein Databank (PDB) Advisory Committee, the Nomenclature Committee of the International Union of Pharmacology (IUPHAR), the UniProt Scientific Advisory Board, and several advisory panels for university-based research institutes. Talk abstract:Innovation at the InterfaceThe question of who should own science assuredly begs the question of whether anybody should own science. This more fundamental issue tends to pit one set of ideals surrounding science, mainly to do with discovery, against others centered on invention. I will consider some historical origins of our divergent attitudes toward pure and applied science, and in that context address the question of how best to stimulate innovation, the stated intent of intellectual property laws. Policies and initiatives intended to promote innovation at the interface of academia and industry have taken one approach, focused on entrepreneurship, technology transfer, patents, royalties, and the like. Might there be alternative approaches that take better account of both the underlying economics and the traditional ideals of science? Stuart Parkinson
Stuart became Executive Director of Scientists for Global Responsibility (SGR) in 2003. SGR is a UK-based organisation, with over 1000 members mainly drawn from the science and engineering professions, whose aim is to 'promote ethical science, design and technology'. During his time in this post, he has edited/authored numerous reports, briefings and articles, including in-depth reports on commercial and military influence on science and technology. Dr. Stuart Parkinson, Scientists For Global Responsibility, Folkestone, UK Talk abstract:The detrimental effects of corporate influence on science and technologyMany policy-makers, business leaders and members of the science community are very supportive of the much closer links that have been developed between commerce and the universities in recent years. They argue that this change is positive for both science and society. However, there is growing evidence that the science commercialisation agenda brings with it a wide range of detrimental effects. These include:
This talk will summarise evidence of problems across five sectors: pharmaceuticals; tobacco; military/defence; oil and gas; and biotechnology. It will also suggest a range of proposals for improving the openness, independence and reliability of academic research. Gábor Lamm
After spending three years as a research scientist at the Boehringer Ingelheim Institute of Molecular Pathology (IMP) in Vienna, Dr. Lamm joined Wacker Chemie, a major global supplier of silicone and polymer raw materials and semi-conductors. At Wacker Chemie, Dr. Lamm was Business-Team Leader in the division specialising in advanced ceramic components for high-tech applications. As of October 2000 he is Managing Director of EMBL Enterprise Management Technology Transfer GmbH, the wholly owned subsidiary of the European Molecular Biology Laboratory. Dr. Lamm is an alumnus of the European Molecular Biology Laboratory Ph.D. program and of the Boehringer Ingelheim Fonds, is co-founder of the EMBL Technology Fund (ETF). He is on the board of directors of the BioRegio RND e. V. (Heidelberg) and former vice-president (2002-2006) of the Association of European Science and Technology Transfer Professionals (ASTP). Talk abstract:Innovation Works: Putting Science to WorkAre we in the golden age of “pure” science or is it behind us? Is the concept of scientific research with “no strings attached” a fata morgana and has it ever been thus? Is the “ownership” of science really a central problem? Is the influence of industry/commerce on basic research detrimental or rather a natural evolution of the scientific environment we live in? The talk will address these questions both from an historic perspective as well as using real case examples to demonstrate that, if properly managed, interaction between academic research and industry is essential and brings benefit(s) not only to both parties but ultimately to society which foots the bill for public research. RegistrationRegistration is free and open to all. To secure a place, please call the Cambridge Science Festival registration hotline: 01223 766766. If you require shuttle bus transport from the Genome Campus, please indicate your requirements >> hereLocationThe venue for the symposium is lecture room 9 in the Mill Lane Lecture Rooms, Mill Lane, Cambridge. It is located in the city centre within walking distance (about 20 min) from the station. Maps and directions can be found here. Accommodation &TravelPlease organise your own accommodation and travelA comprehensive range of accommodation in central Cambridge can be found at smoothhound. Inexpensive flights are available to London Stansted Airport from many locations in Europe. From Cambridge Station you can get direct trains to London Liverpool Street, London King's Cross and Stansted Airport. For train timetables please see the National Rail website. ContactIf you have any enquiries regarding the conference please send an e-mail to science_ownership@ebi.ac.uk ![]() |